NC
NXTM

Nicholas Company’s NxStage Medical Inc. NXTM Stock Holding History

Nicholas Company’s Portfolio NXTM Stock Details NXTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,000
Closed – – 270
2013
Q4 		$0 Sell
1,000
-170,810
-99% -$1.94M ﹤0.01% 285
2013
Q3 		$2.26M Buy
171,810
+41,050
+31% +$538K 0.06% 221
2013
Q2 		$1.87M Buy
+130,760
New +$1.64M 0.06% 220

Other funds holding NXTM

GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BA
Broadview Advisors Milwaukee, Wisconsin $324M AUM 0.76% 1-Year Est. Return

Nicholas Company's NXTM Position: Q1 2014 in Review

Nicholas Company sold out of NxStage Medical Inc. (NXTM) in Q1 2014, closing a stake of 1,000 shares.

Nicholas Company first reported a position in NXTM in Q2 2013 and held it in 3 quarters. The position peaked at $2.26M in Q3 2013. 114 funds tracked by Wall St. Rank hold NXTM as of Q1 2014.

  • Nicholas Company reported no remaining NxStage Medical Inc. position as of Q1 2014 after selling out during the quarter.
  • Nicholas Company sold 1,000 NxStage Medical Inc. shares in Q1 2014.
  • Nicholas Company first reported a position in NxStage Medical Inc. in Q2 2013 and held it in 3 quarters.
  • Nicholas Company's NxStage Medical Inc. position peaked at $2.26M in Q3 2013.
  • 114 funds tracked by Wall St. Rank held NxStage Medical Inc. as of Q1 2014.

Based on Nicholas Company's 13F filing for Q1 2014, filed 9 May 2014.